Potential novel targets: Protease-activated receptors in idiopathic pulmonary

ABSTRACT

[1]  T. Peretz,et al.  Cellular and Molecular Life Sciences Protease‑activated‑receptor‑2 Affects Protease‑activated‑receptor‑1‑driven Breast Cancer , 2022 .

[2]  Thomas H. Smith,et al.  Cofactoring and Dimerization of Proteinase-Activated Receptors , 2013, Pharmacological Reviews.

[3]  Carla M. T. Bauer,et al.  Bleomycin Induces Molecular Changes Directly Relevant to Idiopathic Pulmonary Fibrosis: A Model for “Active” Disease , 2013, PloS one.

[4]  J. Trejo,et al.  Transactivation of the PAR1-PAR2 Heterodimer by Thrombin Elicits β-Arrestin-mediated Endosomal Signaling* , 2013, The Journal of Biological Chemistry.

[5]  J. Goo,et al.  Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis. , 2013, Respiratory medicine.

[6]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[7]  K. Borensztajn,et al.  Protease-activated receptor-4 deficiency does not protect against bleomycin-induced pulmonary fibrosis in mice , 2012, European Respiratory Journal.

[8]  T. van der Poll,et al.  CCAAT/enhancer-binding protein δ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner , 2012, Proceedings of the National Academy of Sciences.

[9]  M. Hollenberg,et al.  Targeting proteinase-activated receptors: therapeutic potential and challenges , 2012, Nature Reviews Drug Discovery.

[10]  S. Sharifi,et al.  Protease-Activated Receptor-2 Modulates Protease-Activated Receptor-1–Driven Neointimal Hyperplasia , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[11]  J. Trejo,et al.  Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through β-arrestin and dishevelled-2 scaffolds , 2011, Proceedings of the National Academy of Sciences.

[12]  A. Kuliopulos,et al.  Matrix metalloproteases and PAR1 activation. , 2011, Blood.

[13]  S. Opal,et al.  A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis , 2011, EMBO molecular medicine.

[14]  K. Preissner,et al.  Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[15]  W. Lawson,et al.  Progress Toward Improving Animal Models for Idiopathic Pulmonary Fibrosis , 2011, The American journal of the medical sciences.

[16]  A. Bohm,et al.  Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins , 2011, Proceedings of the National Academy of Sciences.

[17]  N. Mackman,et al.  Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. , 2010, Blood.

[18]  L. Gleaves,et al.  Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[19]  Michael R Dores,et al.  Signal transduction by protease‐activated receptors , 2010, British journal of pharmacology.

[20]  R. Bois,et al.  Strategies for treating idiopathic pulmonary fibrosis , 2010, Nature Reviews Drug Discovery.

[21]  G. Raghu,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[22]  R. Strieter,et al.  New mechanisms of pulmonary fibrosis. , 2009, Chest.

[23]  A. Nicholson,et al.  Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. , 2009, The Journal of clinical investigation.

[24]  C. Derian,et al.  'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage , 2007, Nature Immunology.

[25]  D. Massi,et al.  Analysis of protease‐activated receptor‐1 and ‐2 in human scar formation , 2007, The Journal of pathology.

[26]  G. Reiser,et al.  A novel therapeutic target in various lung diseases: airway proteases and protease-activated receptors. , 2007, Pharmacology & therapeutics.

[27]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[28]  M. Hollenberg,et al.  High Expression of Pulmonary Proteinase-activated Receptor 2 in Acute and Chronic Lung Injury in Preterm Infants , 2005, Pediatric Research.

[29]  R. Johns,et al.  Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. , 2005, The American journal of pathology.

[30]  T. Welte,et al.  Protease-activated receptor-1 in human lung fibroblasts mediates a negative feedback downregulation via prostaglandin E2. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[31]  L. Brass,et al.  Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. , 2004, Molecular cancer research : MCR.

[32]  Simon C Watkins,et al.  Necrotic Cell Death in Response to Oxidant Stress Involves the Activation of the Apoptogenic Caspase-8/Bid Pathway* , 2003, Journal of Biological Chemistry.

[33]  A. Kuliopulos,et al.  Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation , 2002, Nature Medicine.

[34]  G. Izbicki,et al.  Time course of bleomycin‐induced lung fibrosis , 2002, International journal of experimental pathology.

[35]  R. Silver,et al.  Thrombin Differentiates Normal Lung Fibroblasts to a Myofibroblast Phenotype via the Proteolytically Activated Receptor-1 and a Protein Kinase C-dependent Pathway* , 2001, The Journal of Biological Chemistry.

[36]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[37]  S. Coughlin,et al.  Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Scarborough,et al.  Ligand Cross-reactivity within the Protease-activated Receptor Family* , 1996, The Journal of Biological Chemistry.

[39]  T. van der Poll,et al.  Infectious diseases and fibrotic disorders : Potential novel targets , 2014 .

[40]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[41]  M. D. den Bakker,et al.  Cardiovascular , Pulmonary and Renal Pathology Protease-Activated Receptor-2 Induces Myofibroblast Differentiation and Tissue Factor Up-Regulation during Bleomycin-Induced Lung Injury Potential Role in Pulmonary Fibrosis , 2010 .

[42]  P. Reitsma,et al.  Cardiovascular , Pulmonary and Renal Pathology Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation , 2010 .

[43]  N. Prévost,et al.  Thrombin Responses in Human Endothelial Cells CONTRIBUTIONS FROM RECEPTORS OTHER THAN PAR1 INCLUDE THE TRANSACTIVATION OF PAR2 BY THROMBIN-CLEAVED PAR1* , 2000 .

[44]  T. Peretz,et al.  Cellular and Molecular Life Sciences Protease‑activated‑receptor‑2 Affects Protease‑activated‑receptor‑1‑driven Breast Cancer , 2022 .